Senate Health Cmte. Drug Safety Focus Will Be Antidepressants, Not Vioxx
Executive Summary
The Senate Health Committee's oversight of FDA's drug safety regulation is likely to focus on the agency's handling of antidepressants
You may also be interested in...
Drug Safety User Fees Explored By Sen. Grassley In Questions For Crawford
Senate Finance Committee Chairman Charles Grassley is interested in the idea of funding FDA's drug safety activities with user fees
Drug Safety User Fees Explored By Sen. Grassley In Questions For Crawford
Senate Finance Committee Chairman Charles Grassley is interested in the idea of funding FDA's drug safety activities with user fees
Drug Safety Changes Should Await IoM, HHS Secretary Tells Congress
HHS Secretary Michael Leavitt is urging Congress to be patient in considering potential changes to FDA's regulation of drug safety